BridgeBio Positive 42-Month Results for Acoramidis in ATTR-CM

BridgeBio Pharma, Inc. announced significant findings from the ATTRibute-CM open-label extension study, showcasing the effectiveness of acoramidis, an oral transthyretin stabilizer, in reducing cardiovascular mortality (CVM) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Over 42 months post-randomization, acoramidis demonstrated a 44% reduction in risk of CVM and a 46% reduction in the composite outcome of CVM or first cardiovascular hospitalization (CVH). The drug also showed improved rates of disease stabilization, with a faster clinical benefit observed compared to previous studies. Acoramidis has been approved as Attruby® in the U.S. and BEYONTTRA® in Europe and other regions, indicating its potential to significantly enhance patient outcomes in ATTR-CM.

https://www.quiverquant.com/news/BridgeBio+Pharma+Highlights+Positive+42-Month+Results+for+Acoramidis+in+Reducing+Cardiovascular+Mortality+in+ATTR-CM+Patients